News
AKBA
2.000
+7.53%
0.140
*Akebia Therapeutics 3Q Loss/Shr 10c >AKBA
Dow Jones · 51m ago
*Akebia Therapeutics 3Q Loss $20M >AKBA
Dow Jones · 51m ago
*Akebia Therapeutics 3Q Rev $37.4M >AKBA
Dow Jones · 51m ago
Akebia Therapeutics: Q3 Earnings Snapshot
Barchart · 6h ago
Here's the major earnings before the open tomorrow
Seeking Alpha · 13h ago
Weekly Report: what happened at AKBA last week (1028-1101)?
Weekly Report · 3d ago
Press Release: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dow Jones · 5d ago
Weekly Report: what happened at AKBA last week (1021-1025)?
Weekly Report · 10/28 10:34
Biotech Alert: Searches spiking for these stocks today
TipRanks · 10/25 14:45
Akebia Therapeutics: Strategic Developments and Financial Outlook Drive Buy Rating
TipRanks · 10/23 10:15
GE Aerospace, GM report quarterly earnings beats: Morning Buzz
TipRanks · 10/22 16:01
Akebia stock climbs 8% on dialysis provider supply agreement
Seeking Alpha · 10/22 14:54
Akebia Therapeutics Secures Supply Agreement for Vafseo
TipRanks · 10/22 12:30
Akebia signs commercial supply contract with dialysis organization
TipRanks · 10/22 12:10
Akebia Therapeutics Signs A Multi-Year Commercial Contract With One Of The Nation's Leading Providers Of Kidney Care Services, Expanding Access To Vafseo For Patients On Dialysis; The Contract Enables Physicians To Prescribe Vafseo To Patients On Dialysis As Deemed Clinically Appropriate;' Akebia Expects Vafseo Will Be Available In The U.S. In January 2025.
Benzinga · 10/22 12:10
AKEBIA THERAPEUTICS INC - VAFSEO EXPECTED TO BE AVAILABLE IN U.S. IN JANUARY 2025
Reuters · 10/22 12:00
Weekly Report: what happened at AKBA last week (1014-1018)?
Weekly Report · 10/21 10:32
AKEBIA THERAPEUTICS INC: PURSUANT TO AMENDMENT, TERM OF SUPPLY AGREEMENT IS EXTENDED UNTIL JANUARY 1, 2032
Reuters · 10/16 11:39
Weekly Report: what happened at AKBA last week (1007-1011)?
Weekly Report · 10/14 10:51
Strong Market Entry and Potential for Akebia’s Vafseo Backed by Buy Rating
TipRanks · 10/11 11:27
More
Webull provides a variety of real-time AKBA stock news. You can receive the latest news about Akebia Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About AKBA
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.